Greenwood Capital Associates’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14M | Sell |
11,650
-364
| -3% | -$372K | 1.37% | 14 |
|
|
2026
Q1 | $11M | Sell |
12,014
-411
| -3% | -$417K | 1.22% | 16 |
|
|
2025
Q4 | $13.4M | Sell |
12,425
-744
| -6% | -$711K | 1.45% | 12 |
|
|
2025
Q3 | $10M | Buy |
13,169
+2,673
| +25% | +$1.99M | 1.16% | 18 |
|
|
2025
Q2 | $8.18M | Sell |
10,496
-153
| -1% | -$119K | 1.02% | 24 |
|
|
2025
Q1 | $8.79M | Sell |
10,649
-164
| -2% | -$136K | 1.19% | 21 |
|
|
2024
Q4 | $8.35M | Sell |
10,813
-99
| -0.9% | -$82K | 1.09% | 23 |
|
|
2024
Q3 | $9.67M | Sell |
10,912
-597
| -5% | -$537K | 1.26% | 15 |
|
|
2024
Q2 | $10.4M | Sell |
11,509
-636
| -5% | -$509K | 1.37% | 14 |
|
|
2024
Q1 | $9.45M | Sell |
12,145
-2,085
| -15% | -$1.48M | 1.26% | 21 |
|
|
2023
Q4 | $8.29M | Sell |
14,230
-399
| -3% | -$233K | 1.07% | 28 |
|
|
2023
Q3 | $7.86M | Sell |
14,629
-2,266
| -13% | -$1.17M | 1.14% | 26 |
|
|
2023
Q2 | $7.92M | Sell |
16,895
-4,632
| -22% | -$1.94M | 1.11% | 29 |
|
|
2023
Q1 | $7.39M | Buy |
21,527
+2,359
| +12% | +$796K | 1.06% | 32 |
|
|
2022
Q4 | $7.01M | Sell |
19,168
-1,271
| -6% | -$451K | 1.15% | 30 |
|
|
2022
Q3 | $6.61M | Sell |
20,439
-332
| -2% | -$105K | 1.13% | 31 |
|
|
2022
Q2 | $6.73M | Buy |
20,771
+20,710
| +33,951% | +$6.22M | 1.08% | 32 |
|
|
2022
Q1 | $17K | Sell |
61
-41,221
| -100% | -$10.6M | ﹤0.01% | 193 |
|
|
2021
Q4 | $11.4M | Sell |
41,282
-502
| -1% | -$127K | 1.61% | 16 |
|
|
2021
Q3 | $9.65M | Buy |
41,784
+4,991
| +14% | +$1.23M | 1.48% | 18 |
|
|
2021
Q2 | $8.45M | Sell |
36,793
-443
| -1% | -$89K | 1.28% | 26 |
|
|
2021
Q1 | $6.96M | Sell |
37,236
-5,786
| -13% | -$1.13M | 1.09% | 30 |
|
|
2020
Q4 | $7.26M | Sell |
43,022
-928
| -2% | -$139K | 1.22% | 29 |
|
|
2020
Q3 | $6.5M | Buy |
43,950
+5,289
| +14% | +$819K | 1.26% | 29 |
|
|
2020
Q2 | $6.35M | Sell |
38,661
-9,291
| -19% | -$1.43M | 1.45% | 25 |
|
|
2020
Q1 | $6.65M | Buy |
47,952
+2,336
| +5% | +$321K | 1.95% | 14 |
|
|
2019
Q4 | $6M | Buy |
45,616
+16,507
| +57% | +$1.91M | 1.26% | 26 |
|
|
2019
Q3 | $3.25M | Buy |
+29,109
| New | +$3.24M | 0.79% | 48 |
|
|
2017
Q3 | – | Sell |
-52,025
| Closed | -$4.28M | – | 217 |
|
|
2017
Q2 | $4.28M | Buy |
52,025
+3,551
| +7% | +$290K | 1.11% | 30 |
|
|
2017
Q1 | $4.08M | Buy |
48,474
+677
| +1% | +$54.2K | 1.07% | 31 |
|
|
2016
Q4 | $3.52M | Buy |
47,797
+360
| +0.8% | +$26.8K | 0.99% | 37 |
|
|
2016
Q3 | $3.81M | Sell |
47,437
-121
| -0.3% | -$9.69K | 1.16% | 27 |
|
|
2016
Q2 | $3.75M | Sell |
47,558
-588
| -1% | -$44.3K | 1.15% | 27 |
|
|
2016
Q1 | $3.47M | Buy |
48,146
+5,320
| +12% | +$403K | 1.09% | 37 |
|
|
2015
Q4 | $3.61M | Buy |
42,826
+7,727
| +22% | +$641K | 1.17% | 36 |
|
|
2015
Q3 | $2.94M | Sell |
35,099
-1,127
| -3% | -$95.1K | 1.04% | 39 |
|
|
2015
Q2 | $3.02M | Sell |
36,226
-1,156
| -3% | -$88.1K | 0.91% | 49 |
|
|
2015
Q1 | $2.71M | Sell |
37,382
-228
| -0.6% | -$16.2K | 0.78% | 58 |
|
|
2014
Q4 | $2.6M | Buy |
+37,610
| New | +$2.54M | 0.75% | 62 |
|
|
2013
Q4 | – | Sell |
-42,293
| Closed | -$2.13M | – | 113 |
|
|
2013
Q3 | $2.13M | Sell |
42,293
-13,319
| -24% | -$697K | 0.75% | 65 |
|
|
2013
Q2 | $2.73M | Buy |
+55,612
| New | +$3.03M | 1.19% | 33 |
|
Other funds holding LLY
Greenwood Capital Associates's LLY Position: Q2 2026 in Review
Greenwood Capital Associates reduced its Eli Lilly (LLY) stake by 3% in Q2 2026, selling an estimated $372K and leaving 11,650 shares worth $14M. The position accounts for 1.37% of the portfolio, ranked #14.
Greenwood Capital Associates first reported a position in LLY in Q2 2013 and has held it in 41 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Greenwood Capital Associates held 11,650 shares of Eli Lilly worth $14M as of Q2 2026.
- Greenwood Capital Associates sold 364 Eli Lilly shares in Q2 2026, an estimated $372K.
- Eli Lilly made up 1.37% of Greenwood Capital Associates's portfolio in Q2 2026, its #14 holding.
- Greenwood Capital Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 41 quarters since.
- 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.